New TyHGB Biomarker Could Revolutionize Heart Disease Prediction in Elderly

Researchers have developed a new biomarker called TyHGB to predict cardiovascular disease in elderly populations. The index combines metabolic and blood-based measurements to improve accuracy beyond traditional risk markers. Early studies show it could play a key role in preventing heart-related issues in older adults. TyHGB merges the triglyceride-glucose (TyG) index with haemoglobin (HGB) levels. This fusion creates a more precise tool for assessing cardiovascular risk than body mass index, fasting glucose, or the TyG index alone.

Testing in elderly groups has confirmed its effectiveness. Higher TyHGB levels are linked to a greater likelihood of cardiovascular events in older individuals. The index uses parameters already collected in routine clinical checks, making it practical and easy to implement.

Its validation fills a long-standing gap in cardiovascular prevention for aging populations. Clinicians could use TyHGB to identify high-risk patients early and start preventive treatments sooner. The marker may also become a standard in cardiogeriatrics, a trial endpoint, or a way to track how well therapies work. TyHGB offers a simple yet powerful way to predict heart disease in the elderly. Further studies will examine how changes in its levels over time affect risk and how it interacts with other emerging biomarkers. Its adoption could improve early intervention and patient outcomes in clinical settings.